Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Other Non Operating Income (2022 - 2025)

Stoke Therapeutics (STOK) has 4 years of Other Non Operating Income data on record, last reported at $3000.0 in Q3 2025.

  • For Q3 2025, Other Non Operating Income fell 89.29% year-over-year to $3000.0; the TTM value through Sep 2025 reached $260000.0, up 163.88%, while the annual FY2024 figure was -$247000.0, 248.8% down from the prior year.
  • Other Non Operating Income reached $3000.0 in Q3 2025 per STOK's latest filing, down from $28000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $201000.0 in Q4 2024 and bottomed at -$428000.0 in Q1 2024.
  • Average Other Non Operating Income over 4 years is $9600.0, with a median of $41000.0 recorded in 2022.
  • The widest YoY moves for Other Non Operating Income: up 390.24% in 2024, down 1119.05% in 2024.
  • A 4-year view of Other Non Operating Income shows it stood at $42000.0 in 2022, then fell by 2.38% to $41000.0 in 2023, then skyrocketed by 390.24% to $201000.0 in 2024, then tumbled by 98.51% to $3000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non Operating Income were $3000.0 in Q3 2025, $28000.0 in Q2 2025, and $28000.0 in Q1 2025.